Moderna shares plunge around 25% amid reported cancer-vaccine data leak

The Wall Street Journal put Moderna’s intraday drop at around 25% on Oct. 22 after cancer-vaccine study details circulated on social media. Barron’s reported that an Oncology Central article was pulled before the information spread online. CNBC later reported that fuller Phase 3 results had been released Thursday and appeared positive relative to Wall Street expectations. Its reported risk reductions concern certain melanoma patients, not all cancers.